Dermata Historical Balance Sheet

DRMA Stock

USD 1.42 0.07 5.19%

Trend analysis of Dermata Therapeutics balance sheet accounts such as Other Current Liabilities of 730.3 K or Total Current Liabilities of 1.5 M provides information on Dermata Therapeutics' total assets, liabilities, and equity, which is the actual value of Dermata Therapeutics to its prevalent stockholders. By breaking down trends over time using Dermata Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Dermata Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Dermata Therapeutics is a good buy for the upcoming year.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.

About Dermata Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Dermata Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Dermata Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Dermata Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Dermata currently owns. An asset can also be divided into two categories, current and non-current.

Dermata Therapeutics Balance Sheet Chart

At present, Dermata Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 1.6 B, whereas Other Current Liabilities is forecasted to decline to about 730.3 K.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Total Assets

Total assets refers to the total amount of Dermata Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Dermata Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Dermata Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Dermata Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Dermata Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Dermata Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.At present, Dermata Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 1.6 B, whereas Other Current Liabilities is forecasted to decline to about 730.3 K.

	2024	2025 (projected)
Short and Long Term Debt Total	4.1M	2.7M
Total Assets	3.5B	3.7B

Short Long Term Debt Total Total Assets

Dermata Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock
Total Assets		0.43	0.6	-0.03	1.0	0.56	-0.95	-0.12	-1.0	0.54	0.15	-0.1	-0.95	1.0	0.97	0.9	0.43	1.0	1.0	-0.11	0.57	0.41	1.0	-0.01	0.41	-0.56
Short Long Term Debt Total	0.43		0.46	0.18	0.44	0.81	-0.33	-0.58	-0.44	0.6	0.62	0.33	-0.33	0.43	0.37	0.55	0.84	0.43	0.43	0.6	0.96	1.0	0.43	0.53	1.0	-0.84
Other Current Liab	0.6	0.46		-0.38	0.61	0.74	-0.46	-0.68	-0.61	0.82	0.61	0.47	-0.46	0.6	0.5	0.65	0.7	0.6	0.6	0.48	0.46	0.45	0.6	0.6	0.45	-0.7
Total Current Liabilities	-0.03	0.18	-0.38		-0.03	-0.37	0.07	0.56	0.02	-0.43	-0.45	-0.13	0.07	-0.03	-0.05	-0.05	-0.34	-0.02	-0.02	-0.38	0.13	0.18	-0.03	-0.57	0.18	0.33
Total Stockholder Equity	1.0	0.44	0.61	-0.03		0.57	-0.95	-0.14	-1.0	0.56	0.17	-0.09	-0.95	1.0	0.97	0.91	0.45	1.0	1.0	-0.09	0.59	0.42	1.0	0.01	0.42	-0.58
Net Tangible Assets	0.56	0.81	0.74	-0.37	0.57		-0.52	-0.86	-0.55	0.84	0.86	0.43	-0.52	0.56	0.49	0.68	0.97	0.55	0.55	0.74	0.85	0.8	0.56	0.79	0.8	-1.0
Current Deferred Revenue	-0.95	-0.33	-0.46	0.07	-0.95	-0.52		0.12	0.93	-0.44	-0.19	0.1	1.0	-0.95	-0.92	-0.86	-0.37	-0.95	-0.95	0.11	-0.55	-0.31	-0.95	0.01	-0.31	0.53
Net Debt	-0.12	-0.58	-0.68	0.56	-0.14	-0.86	0.12		0.12	-0.71	-0.98	-0.68	0.12	-0.12	-0.06	-0.3	-0.89	-0.12	-0.12	-0.95	-0.57	-0.58	-0.12	-0.99	-0.58	0.83
Retained Earnings	-1.0	-0.44	-0.61	0.02	-1.0	-0.55	0.93	0.12		-0.55	-0.14	0.1	0.93	-1.0	-0.97	-0.9	-0.43	-1.0	-1.0	0.11	-0.57	-0.42	-1.0	0.01	-0.42	0.56
Accounts Payable	0.54	0.6	0.82	-0.43	0.56	0.84	-0.44	-0.71	-0.55		0.64	0.12	-0.44	0.54	0.39	0.78	0.75	0.54	0.54	0.52	0.6	0.59	0.54	0.63	0.59	-0.84
Cash	0.15	0.62	0.61	-0.45	0.17	0.86	-0.19	-0.98	-0.14	0.64		0.72	-0.19	0.15	0.09	0.31	0.89	0.15	0.15	0.95	0.64	0.62	0.15	0.96	0.62	-0.84
Non Current Assets Total	-0.1	0.33	0.47	-0.13	-0.09	0.43	0.1	-0.68	0.1	0.12	0.72		0.1	-0.1	-0.09	-0.13	0.55	-0.1	-0.1	0.76	0.29	0.33	-0.1	0.71	0.33	-0.37
Long Term Debt	-0.95	-0.33	-0.46	0.07	-0.95	-0.52	1.0	0.12	0.93	-0.44	-0.19	0.1		-0.95	-0.92	-0.86	-0.37	-0.95	-0.95	0.11	-0.55	-0.31	-0.95	0.01	-0.31	0.53
Cash And Short Term Investments	1.0	0.43	0.6	-0.03	1.0	0.56	-0.95	-0.12	-1.0	0.54	0.15	-0.1	-0.95		0.97	0.9	0.43	1.0	1.0	-0.11	0.57	0.41	1.0	-0.01	0.41	-0.56
Common Stock Shares Outstanding	0.97	0.37	0.5	-0.05	0.97	0.49	-0.92	-0.06	-0.97	0.39	0.09	-0.09	-0.92	0.97		0.77	0.39	0.97	0.97	-0.15	0.52	0.35	0.97	-0.05	0.35	-0.5
Non Current Liabilities Total	0.9	0.55	0.65	-0.05	0.91	0.68	-0.86	-0.3	-0.9	0.78	0.31	-0.13	-0.86	0.9	0.77		0.52	0.9	0.9	0.07	0.67	0.53	0.9	0.16	0.53	-0.7
Other Current Assets	0.43	0.84	0.7	-0.34	0.45	0.97	-0.37	-0.89	-0.43	0.75	0.89	0.55	-0.37	0.43	0.39	0.52		0.42	0.42	0.83	0.84	0.84	0.43	0.85	0.84	-0.97
Other Stockholder Equity	1.0	0.43	0.6	-0.02	1.0	0.55	-0.95	-0.12	-1.0	0.54	0.15	-0.1	-0.95	1.0	0.97	0.9	0.42		1.0	-0.11	0.57	0.41	1.0	-0.01	0.41	-0.56
Total Liab	1.0	0.43	0.6	-0.02	1.0	0.55	-0.95	-0.12	-1.0	0.54	0.15	-0.1	-0.95	1.0	0.97	0.9	0.42	1.0		-0.11	0.57	0.41	1.0	-0.01	0.41	-0.56
Net Invested Capital	-0.11	0.6	0.48	-0.38	-0.09	0.74	0.11	-0.95	0.11	0.52	0.95	0.76	0.11	-0.11	-0.15	0.07	0.83	-0.11	-0.11		0.55	0.61	-0.11	0.97	0.61	-0.72
Property Plant And Equipment Gross	0.57	0.96	0.46	0.13	0.59	0.85	-0.55	-0.57	-0.57	0.6	0.64	0.29	-0.55	0.57	0.52	0.67	0.84	0.57	0.57	0.55		0.95	0.57	0.5	0.95	-0.88
Short Long Term Debt	0.41	1.0	0.45	0.18	0.42	0.8	-0.31	-0.58	-0.42	0.59	0.62	0.33	-0.31	0.41	0.35	0.53	0.84	0.41	0.41	0.61	0.95		0.41	0.54	1.0	-0.83
Total Current Assets	1.0	0.43	0.6	-0.03	1.0	0.56	-0.95	-0.12	-1.0	0.54	0.15	-0.1	-0.95	1.0	0.97	0.9	0.43	1.0	1.0	-0.11	0.57	0.41		-0.01	0.41	-0.56
Net Working Capital	-0.01	0.53	0.6	-0.57	0.01	0.79	0.01	-0.99	0.01	0.63	0.96	0.71	0.01	-0.01	-0.05	0.16	0.85	-0.01	-0.01	0.97	0.5	0.54	-0.01		0.54	-0.76
Short Term Debt	0.41	1.0	0.45	0.18	0.42	0.8	-0.31	-0.58	-0.42	0.59	0.62	0.33	-0.31	0.41	0.35	0.53	0.84	0.41	0.41	0.61	0.95	1.0	0.41	0.54		-0.83
Common Stock	-0.56	-0.84	-0.7	0.33	-0.58	-1.0	0.53	0.83	0.56	-0.84	-0.84	-0.37	0.53	-0.56	-0.5	-0.7	-0.97	-0.56	-0.56	-0.72	-0.88	-0.83	-0.56	-0.76	-0.83

Click cells to compare fundamentals

Dermata Therapeutics Account Relationship Matchups

Dermata Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	605.5K	11.6M	6.9M	8.0M	3.5B	3.7B
Other Current Liab	133.5K	1.0M	425.9K	757.6K	1.2M	730.3K
Total Current Liabilities	3.8M	1.5M	922.6K	1.6M	2.0M	1.5M
Total Stockholder Equity	(28.1M)	10.1M	6.0M	6.4M	1.6B	1.6B
Net Debt	3.0M	(10.8M)	(6.2M)	(7.4M)	(3.2M)	(3.3M)
Retained Earnings	(28.1M)	(36.0M)	(45.6M)	(53.4M)	(65.7B)	(62.4B)
Accounts Payable	104.3K	515.2K	496.7K	866.0K	808.0K	573.4K
Cash	530.4K	10.8M	6.2M	7.4M	3.2M	5.5M
Cash And Short Term Investments	530.4K	10.8M	6.2M	7.4M	3.2B	3.3B
Liabilities And Stockholders Equity	3.8M	11.6M	6.9M	8.0M	3.5B	3.7B
Non Current Liabilities Total	3.6M	515.2K	496.7K	757.6M	1.2B	1.2B
Other Current Assets	75.1K	825.1K	690.6K	532.1K	612.0K	483.3K
Other Stockholder Equity	81.1M	46.1M	51.6M	59.7M	67.2B	70.6B
Total Liab	3.8M	1.5M	922.6K	1.6M	2.0B	2.1B
Net Invested Capital	367.7K	10.1M	6.0M	6.4M	1.6M	1.5M
Total Current Assets	605.5K	11.6M	6.9M	8.0M	3.2B	3.3B
Net Working Capital	(3.2M)	10.1M	6.0M	6.4M	1.6M	1.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:

How To Invest In Dermata

Details

Is Dermata Stock a good investment?

Details

What is Dermata Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(8.03)

Return On Assets

(1.36)

Return On Equity

(3.10)

The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dermata Historical Balance Sheet

About Dermata Balance Sheet Analysis

Dermata Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Dermata Therapeutics balance sheet Correlations

Dermata Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Dermata Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Other Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Short Long Term Debt	+ 1.0	Short Long Term Debt Total

Total Current Assets	- 1.0	Retained Earnings
Total Liab	- 1.0	Retained Earnings
Other Stockholder Equity	- 1.0	Retained Earnings
Cash And Short Term Investments	- 1.0	Retained Earnings
Common Stock	- 1.0	Net Tangible Assets
Retained Earnings	- 1.0	Total Stockholder Equity